AbbVie Inc. $ABBV Shares Acquired by Rakuten Investment Management Inc.

Rakuten Investment Management Inc. grew its stake in shares of AbbVie Inc. (NYSE:ABBV) by 9.7% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 317,156 shares of the company’s stock after acquiring an additional 28,065 shares during the period. Rakuten Investment Management Inc.’s holdings in AbbVie were worth $83,504,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Verus Financial Partners Inc. increased its holdings in AbbVie by 1.7% during the 3rd quarter. Verus Financial Partners Inc. now owns 2,048 shares of the company’s stock worth $536,000 after acquiring an additional 35 shares during the period. Evergreen Private Wealth LLC lifted its stake in AbbVie by 3.3% in the 3rd quarter. Evergreen Private Wealth LLC now owns 1,090 shares of the company’s stock worth $285,000 after purchasing an additional 35 shares in the last quarter. Lifelong Wealth Advisors Inc. lifted its stake in AbbVie by 2.1% in the 3rd quarter. Lifelong Wealth Advisors Inc. now owns 1,755 shares of the company’s stock worth $459,000 after purchasing an additional 36 shares in the last quarter. IMG Wealth Management Inc. boosted its holdings in AbbVie by 22.8% in the 3rd quarter. IMG Wealth Management Inc. now owns 194 shares of the company’s stock valued at $51,000 after purchasing an additional 36 shares during the period. Finally, Foundry Financial Group Inc. boosted its holdings in AbbVie by 4.6% in the 3rd quarter. Foundry Financial Group Inc. now owns 839 shares of the company’s stock valued at $219,000 after purchasing an additional 37 shares during the period. 70.23% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie raised its 2026 outlook, projecting EPS of $13.95–$13.99 and revenue of $67.8 billion, both slightly above consensus at the midpoint. Its latest quarter also beat analyst estimates, with revenue up 10.3% year over year. Q3 earnings outlook and pipeline progress
• Positive Sentiment: AbbVie expanded its Oxford R&D facility as part of an investment exceeding £120 million, signaling continued commitment to research and development. Reuters: Oxford R&D expansion
• Positive Sentiment: The company expanded its migraine-drug partnership with Brise in a deal potentially worth up to $757 million, adding to its pipeline prospects. AbbVie-Brise license deal
• Positive Sentiment: Several analysts raised their price targets after the quarterly results, reflecting confidence in AbbVie’s growth transition. Analyst target increases
• Negative Sentiment: Fourth-quarter EPS guidance of $3.83–$3.87 is below the $3.89 consensus, despite revenue guidance of $18.4 billion topping expectations. That earnings shortfall could temper the otherwise stronger full-year outlook.
• Negative Sentiment: After a strong run, valuation concerns remain: one recent analysis described the shares as stretched and questioned how much further growth from Skyrizi and pipeline deals is already reflected in the price. Valuation and upside analysis

Insider Transactions at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.06% of the company’s stock.

AbbVie Price Performance

Shares of ABBV opened at $285.88 on Wednesday. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $298.74. The company has a market capitalization of $505.09 billion, a P/E ratio of 49.20, a P/E/G ratio of 1.31 and a beta of 0.20. The firm’s 50 day simple moving average is $270.23 and its 200 day simple moving average is $237.89.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 30th. The company reported $3.82 EPS for the quarter, topping analysts’ consensus estimates of $3.73 by $0.09. The business had revenue of $17.40 billion during the quarter, compared to analysts’ expectations of $17.32 billion. AbbVie had a net margin of 15.67% and a negative return on equity of 435.41%. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.86 EPS. On average, equities analysts anticipate that AbbVie Inc. will post 14.00 earnings per share for the current year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be given a $1.82 dividend. This represents a $7.28 annualized dividend and a yield of 2.5%. This is a boost from AbbVie’s previous quarterly dividend of $1.73. The ex-dividend date is Friday, January 15th. AbbVie’s dividend payout ratio (DPR) is presently 119.10%.

Analysts Set New Price Targets

A number of research analysts have recently commented on ABBV shares. Oppenheimer boosted their price target on shares of AbbVie from $244.00 to $258.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. Royal Bank Of Canada increased their price objective on AbbVie from $280.00 to $330.00 and gave the stock an “outperform” rating in a research report on Monday. Canaccord Genuity Group lifted their price objective on AbbVie from $290.00 to $338.00 and gave the company a “buy” rating in a research note on Monday. BMO Capital Markets boosted their target price on AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Finally, JPMorgan Chase & Co. boosted their target price on AbbVie from $285.00 to $300.00 and gave the stock an “overweight” rating in a research report on Thursday, October 8th. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $296.88.

About AbbVie

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.